← Back to Search

Monoclonal Antibodies

Tocilizumab for Blood Cancers

Phase 2

Waitlist Available

Led By Saurabh Chhabra, MD

Research Sponsored by Medical College of Wisconsin

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 365

Awards & highlights

Study Summary

This trial is testing whether tocilizumab can improve survival after allogeneic hematopoietic cell transplantation for hematologic malignancy.

Eligible Conditions

Blood Cancers

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 365

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 365

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 365 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

The Number of Patients With GVHD/Relapse-free (GRFS) Survival

Side effects data

From 2017 Phase 4 trial • 59 Patients • NCT02034474

11%

Low ANC

nausea

Inpatient admission

fatigue

agranulocytosis

100%

80%

60%

40%

20%

Study treatment Arm

Tocilizumab

Placebo

Trial Design

1Treatment groups

Experimental Treatment

Group I: Tacrolimus/Methotrexate/TocilizumabExperimental Treatment3 Interventions

Patients enrolled on the clinical trial will receive tacrolimus initiating at Day -1 at doses to maintain therapeutic levels per institutional preference and continued until at least Day +90 post-transplant. Methotrexate will be administered intravenously and dosed at 15 mg/m2 Day +1 and 10 mg/m2 Days +3, +6 and +11. Tocilizumab will be administered intravenously at a dose of 8 mg/kg on Day -1 and at day +100 (+/- 14 days).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Tacrolimus

2011

Completed Phase 4

~4740

Methotrexate

2013

Completed Phase 4

~3800

Tocilizumab

2012

Completed Phase 4

~1840

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,662 Previous Clinical Trials

40,925,852 Total Patients Enrolled

1 Trials studying Blood Cancers

70 Patients Enrolled for Blood Cancers

National Heart, Lung, and Blood Institute (NHLBI)NIH

3,836 Previous Clinical Trials

47,850,828 Total Patients Enrolled

Medical College of WisconsinLead Sponsor

609 Previous Clinical Trials

1,162,554 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the cap on enrollment for this research experiment?

"At present, this research is not enrolling any additional participants. It was first published on November 6th 2018 and updated most recently on March 2nd 2022. Fortunately, there are numerous other clinical trials involving malignancies, hematologic diseases or Tocilizumab that have open recruitment: 263 for the former two categories and 415 for the latter."

Answered by AI

What affect does Tocilizumab treatment have on medical conditions?

"Tocilizumab is primarily used to address meningeal leukemia, but can also be employed for the treatment of small cell lung cancer (SCLC), juvenile rheumatoid arthritis, and systemic juvenile idiopathic arthritis (SJIA)."

Answered by AI

Are new participants being taken on at this juncture?

"According to clinicaltrials.gov, this trial is not actively recruiting at the moment; it was first posted on November 6th 2018 and last updated on March 2nd 2022. However, there are presently 678 other trials looking for patients."

Answered by AI

How perilous is the application of Tocilizumab for individuals?

"There is preliminary evidence backing up Tocilizumab's safety, so it was given a rating of 2. In other words, there are some studies which point to its security but no ones that validate its efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant

William R. Drobyski, MD 2018. "PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03699631.